

Amendments to the Specification:

On page 14, please amend the paragraph beginning at line 7 as follows:

A preferred compound according to Formula I is ~~5-(4-(1-carbomethoxy)-2-(3,5-dimethoxyphenyl)-ethenyl)-phenoxy)-benzyl)-2,4-thiazolidinedione~~ 5-(4-(4-(1-carbomethoxy-2-(3,5-dimethoxyphenyl)-ethenyl)-phenoxy)-benzyl)-2,4-thiazolidinedione, hereinafter referred to as Compound VIII. However, it will be appreciated that the invention also contemplates the provision and use of other compounds according to Formula I.

On page 25, please amend the heading beginning at line 4 as follows:

e) Synthesis of ~~5-(4-(1-carbomethoxy)-2-(3,5-dimethoxyphenyl)-ethenyl)-phenoxy)-benzyl)-2,4-thiazolidine dione~~ 5-(4-(4-(1-carbomethoxy-2-(3,5-dimethoxyphenyl)-ethenyl)-phenoxy)-benzyl)-2,4-thiazolidine dione, also called 3-(3,5-dimethoxyphenyl)-2-{4-[4-(2,4-dioxothiazolidin-5-ylmethyl)phenoxy]-phenyl}-acrylic acid methyl ester (Compound VIII):